STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.
Entry into a Material Definitive Agreement. |
Effective December 6, 2016, we entered into extension agreements
to existing consulting agreements dated November 4, 2015, as
amended as of July 20, 2016 and as further amended on September
19, 2016, with two of our directors, Jeffrey F. O’Donnell, Sr.
and Samuel E. Navarro. The amendments extended the termination
dates of two consulting agreements from December 31, 2016 to June
30, 2017. In addition to the extension of the term, the modified
agreements provide that each of the directors shall work with the
President and Chief Executive Officer to establish the specific
duties and objectives to be undertaken by the respective director
during the remaining term of the Agreements. These duties and
objectives shall be communicated to the Chair of the Nominating
and Governance Committee for review and approval. The other terms
of the agreements remain unmodified.
10.1 |
Extension Agreement dated as of December 6, 2016 between Strata Skin Sciences, Inc. and Jeffrey F. O’Donnell, Sr. |
10.2 |
Extension Agreement dated as of December 6, 2016 between Strata Skin Sciences, Inc. and Samuel E. Navarro. |
About STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN)
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment. STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) Recent Trading Information
STRATA SKIN SCIENCES, INC. (NASDAQ:SSKN) closed its last trading session up +0.001 at 0.561 with 637,559 shares trading hands.
